RxDoctor Payments Data

Leah Finkeldei, PA

Physician Assistant · Topeka, KSNPI 1356692230

Payments from drug & device makers

$2,188in general payments, 2019–2025

Across 29 payments — averaging $75.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$1K
  • AbbVie$233
  • Johnson & Johnson$222
  • Bristol Myers Squibb$190
  • Janssen Scientific Affairs, LLC$112
  • Takeda Pharmaceuticals U.S.A., Inc.$108

What the payments were for

  • Travel & lodging$90341%
  • Food & beverage$1,22456%
  • Education$613%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,188 in reported general payments places this provider in the 80th percentile of 1,016 physician assistant providers in Kansas.

See all physician assistant providers in Kansas

Medicare billing

Part B allowed, 2024
$79,354
Medicare patients
465
Services billed
1,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase32$53,150
XifaxanRifaximin14$41,876
LinzessLinaclotide52$34,004
IbsrelaTenapanor Hcl13$22,843
Mesalamine39$15,628
MotegrityPrucalopride Succinate19$11,988
Colestipol Hcl83$7,929
Entecavir12$7,197
Colesevelam Hcl55$6,958
Balsalazide Disodium39$6,454
Dexlansoprazole DrDexlansoprazole35$6,445
Ursodiol41$6,308
Mesalamine ErMesalamine24$5,518
Budesonide DrBudesonide43$3,893
Azathioprine54$3,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$233$87,15584 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$108$11,98819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,016 physician assistant providers in Kansas.

Other physician assistant in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →